Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy
Zhan Shi,1,* Sihui Zhu,2,* Yuncheng Jin,1 Liang Qi,1 Mingzhen Zhou,1 Ziyan Zhou,1 Juan Zhang,1 Baorui Liu,1 Jie Shen1 1Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-02-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/lymphocyte-to-c-reactive-protein-ratio-is-an-independent-predictor-of--peer-reviewed-fulltext-article-JHC |
| _version_ | 1827355412870987776 |
|---|---|
| author | Shi Z Zhu S Jin Y Qi L Zhou M Zhou Z Zhang J Liu B Shen J |
| author_facet | Shi Z Zhu S Jin Y Qi L Zhou M Zhou Z Zhang J Liu B Shen J |
| author_sort | Shi Z |
| collection | DOAJ |
| description | Zhan Shi,1,* Sihui Zhu,2,* Yuncheng Jin,1 Liang Qi,1 Mingzhen Zhou,1 Ziyan Zhou,1 Juan Zhang,1 Baorui Liu,1 Jie Shen1 1Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu Province, 210008, People’s Republic of China; 2The Comprehensive Cancer Centre of Nanjing International Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, 210008, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie Shen; Baorui Liu, Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu Province, 210008, People’s Republic of China, Fax +86-025-83106666, Email shenjie2008nju@163.com; baoruiliu@nju.edu.cnBackground: Stereotactic body radiotherapy (SBRT) has emerged as an alternative approach for patients with hepatocellular carcinoma (HCC), and we aim to find potential prognostic biomarkers for HCC patients who received SBRT.Methods: In this study, we retrospectively analyzed HCC patients who underwent SBRT in our institution from January 2018 to December 2022. The inflammatory parameters, along with baseline patients’ characteristics were collected to elucidate the potential relationship with survival benefits and liver toxicities.Results: Overall, 35 patients were enrolled in our study. For the efficacy population (25 patients who underwent SBRT for primary liver lesions), the objective response rate (ORR) and disease control rate (DCR) were 60% and 100%, respectively. The median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI) 5.6– 14.1 months], and the median overall survival (OS) was 18.5 months (95% CI 14.2– 22.8 months). We further confirmed that higher baseline lymphocyte-C-reactive protein ratio (LCR) (≥ 2361.11) was positively related to both longer PFS (12.0 vs 4.3 months, P = 0.002) and OS (21.9 vs 11.4 months, P = 0.022). Moreover, patients with diabetes and higher alpha-fetoprotein (AFP) (≥ 400 ng/mL) were also found to be associated with worse OS. The most common hepatotoxicity was elevated gamma-glutamyl transferase (GGT) (84.0%).Conclusion: In conclusion, for patients with inoperable HCC, SBRT resulted in satisfactory local control, survival benefits, and acceptable liver toxicity. Pre-radiotherapy LCR might be an independent and readily available predictor for survival, which facilitates us to find the most appropriate treatment options.Keywords: hepatocellular carcinoma, stereotactic body radiotherapy, lymphocyte-C-reactive protein ratio, survival, liver toxicity |
| first_indexed | 2024-03-08T04:11:35Z |
| format | Article |
| id | doaj.art-6d6a73ee960143dbb5168e35ba423343 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-03-08T04:11:35Z |
| publishDate | 2024-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-6d6a73ee960143dbb5168e35ba4233432024-02-08T18:28:26ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692024-02-01Volume 1130531690325Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving RadiotherapyShi ZZhu SJin YQi LZhou MZhou ZZhang JLiu BShen JZhan Shi,1,* Sihui Zhu,2,* Yuncheng Jin,1 Liang Qi,1 Mingzhen Zhou,1 Ziyan Zhou,1 Juan Zhang,1 Baorui Liu,1 Jie Shen1 1Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu Province, 210008, People’s Republic of China; 2The Comprehensive Cancer Centre of Nanjing International Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, 210008, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie Shen; Baorui Liu, Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu Province, 210008, People’s Republic of China, Fax +86-025-83106666, Email shenjie2008nju@163.com; baoruiliu@nju.edu.cnBackground: Stereotactic body radiotherapy (SBRT) has emerged as an alternative approach for patients with hepatocellular carcinoma (HCC), and we aim to find potential prognostic biomarkers for HCC patients who received SBRT.Methods: In this study, we retrospectively analyzed HCC patients who underwent SBRT in our institution from January 2018 to December 2022. The inflammatory parameters, along with baseline patients’ characteristics were collected to elucidate the potential relationship with survival benefits and liver toxicities.Results: Overall, 35 patients were enrolled in our study. For the efficacy population (25 patients who underwent SBRT for primary liver lesions), the objective response rate (ORR) and disease control rate (DCR) were 60% and 100%, respectively. The median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI) 5.6– 14.1 months], and the median overall survival (OS) was 18.5 months (95% CI 14.2– 22.8 months). We further confirmed that higher baseline lymphocyte-C-reactive protein ratio (LCR) (≥ 2361.11) was positively related to both longer PFS (12.0 vs 4.3 months, P = 0.002) and OS (21.9 vs 11.4 months, P = 0.022). Moreover, patients with diabetes and higher alpha-fetoprotein (AFP) (≥ 400 ng/mL) were also found to be associated with worse OS. The most common hepatotoxicity was elevated gamma-glutamyl transferase (GGT) (84.0%).Conclusion: In conclusion, for patients with inoperable HCC, SBRT resulted in satisfactory local control, survival benefits, and acceptable liver toxicity. Pre-radiotherapy LCR might be an independent and readily available predictor for survival, which facilitates us to find the most appropriate treatment options.Keywords: hepatocellular carcinoma, stereotactic body radiotherapy, lymphocyte-C-reactive protein ratio, survival, liver toxicityhttps://www.dovepress.com/lymphocyte-to-c-reactive-protein-ratio-is-an-independent-predictor-of--peer-reviewed-fulltext-article-JHChepatocellular carcinomastereotactic body radiotherapylymphocyte-c-reactive protein ratiosurvivalliver toxicity. |
| spellingShingle | Shi Z Zhu S Jin Y Qi L Zhou M Zhou Z Zhang J Liu B Shen J Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy Journal of Hepatocellular Carcinoma hepatocellular carcinoma stereotactic body radiotherapy lymphocyte-c-reactive protein ratio survival liver toxicity. |
| title | Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy |
| title_full | Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy |
| title_fullStr | Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy |
| title_full_unstemmed | Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy |
| title_short | Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy |
| title_sort | lymphocyte to c reactive protein ratio is an independent predictor of survival benefits for hepatocellular carcinoma patients receiving radiotherapy |
| topic | hepatocellular carcinoma stereotactic body radiotherapy lymphocyte-c-reactive protein ratio survival liver toxicity. |
| url | https://www.dovepress.com/lymphocyte-to-c-reactive-protein-ratio-is-an-independent-predictor-of--peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT shiz lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT zhus lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT jiny lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT qil lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT zhoum lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT zhouz lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT zhangj lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT liub lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy AT shenj lymphocytetocreactiveproteinratioisanindependentpredictorofsurvivalbenefitsforhepatocellularcarcinomapatientsreceivingradiotherapy |